HROW— HARROW, INC.

MaterialsPharmaceuticals$1.5B mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Total revenues	$272.3M+36.4%	$199.6M+53.3%	$130.2M+47.0%	$88.6M
Cost of sales	-$67.9M-38.0%	-$49.2M-24.2%	-$39.6M-56.2%	-$25.4M
Gross profit	$204.4M+35.9%	$150.4M+66.1%	$90.6M+43.3%	$63.2M
Selling, general and administrative	$152.9M+18.5%	$129.1M+55.3%	$83.1M+42.7%	$58.2M
Research and development	$20.9M+71.2%	$12.2M+83.9%	$6.7M+118.1%	$3.0M
Impairment of long-lived assets	$253K-33.4%	$380K	—	—
Total operating expenses	$173.9M+22.8%	$141.5M+57.1%	$90.1M+47.0%	$61.3M
Income from operations	$30.5M+245.9%	$8.8M+1946.9%	$431K-77.5%	$1.9M
Interest expense, net	-$24.2M-6.1%	-$22.8M-6.9%	-$21.3M-194.4%	-$7.2M
Investment (loss) gain from Eton Pharmaceuticals	-$3.2M-202.6%	$3.1M	—	-$2.9M
Loss on extinguishment of debt	-$7.8M-41.8%	-$5.5M	—	—
Other income (expense), net	$47K+125.4%	-$185K+58.3%	-$444K-535.3%	$102K
Total other expense, net	-$31.9M-22.0%	-$26.1M-8.3%	-$24.1M-51.5%	-$15.9M
Loss before income taxes	-$1.4M+92.1%	-$17.3M+27.0%	-$23.7M-69.2%	-$14.0M
Income tax expense	-$3.8M-2242.2%	-$161K+77.0%	-$701K-834.7%	-$75K
Net loss	-$5.1M+70.6%	-$17.5M+28.4%	-$24.4M-73.3%	-$14.1M
Basic net loss per share of common stock	-$0.14+71.4%	-$0.49+34.7%	-$0.75-47.1%	-$0.51
Diluted net loss per share of common stock	-$0.14+71.4%	-$0.49+34.7%	-$0.75-47.1%	-$0.51
Weighted average number of shares of common stock outstanding, basic	36.8M+3.1%	35.7M+9.3%	32.6M+18.8%	27.5M
Weighted average number of shares of common stock outstanding, diluted	36.8M+3.1%	35.7M+9.3%	32.6M+18.8%	27.5M
Product Sales Net [Member]
Other Revenues [Member]

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 12 more years of annual history and full quarterly detail on Pro.

Upgrade to Pro →

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.